Frontlight ResearchEarly access
WithdrawnPhase 1
Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II
Key facts
- Who runs it
- Homology Medicines, Inc
- Where
- Fairfax, Hackensack, New Haven, Oakland, and Salt Lake City, United StatesSee the 5 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 8 Sept 2022
- Expected to end
- Jan 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- Genetic HMI-203
- Record updated
- 28 August 2023
- Why it stopped
- Homology Medicines has discontinued development of this program.
Who can take part
- Age
- 18 years to 45 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Adult males 18-45 years of age at the time of informed consent
- Has capacity and is able to understand the purpose and risks of the study and is willing, able and committed to comply with all study procedures for the duration of the trial (a total of 5 years after gene therapy administration)
- Diagnosis of MPS II based on historically decreased I2S enzyme activity and elevated urine GAGs and/or presence of hemizygous IDS pathogenic variant
- Kaufman Brief Intelligence Test-Second Edition (KBIT2) score ≥ 80
- Compliance with regular treatments of ERT for MPS II for at least 12 months prior to enrollment
- Clinically stable relative to urinary GAG levels, ambulation, and cardiopulmonary status for 12 months preceding enrollment
Who cannot take part
- Presence of anti-capsid neutralizing antibodies
- Contraindication to corticosteroid or tacrolimus use
- Multiple sulfatase disorder as determined by abnormal activity of another lysosomal sulfatase
- History of BMT, stem cell transplant, or gene therapy
- Any condition that would not allow the potential participant to complete follow-up examinations during the course of the study or, in the opinion of the investigator, makes the potential participant unsuitable for the study
- ALT or AST > ULN; Total or Direct bilirubin > ULN
- International normalized ratio (INR) >1.2 ULN
- Hemoglobin A1c ≥ 6.5% or fasting glucose ≥126 mg/dL
- Unresponsive and/or intolerant to idursulfase treatment
- Hematology values below the normal range
Where in United States
Also in 1 other country, 1 site
- Lysosomal and Rare Disorders Research and Treatment Center, IncFairfax, United States
- Hackensack University Medical CenterHackensack, United States
- Yale Center for Clinical InvestigationNew Haven, United States
- UCSF Benioff Children's Hospital OaklandOakland, United States
- University of Utah Pediatric Genetic & Metabolism ClinicSalt Lake City, United States
About the trial
What the trial wants to find out
Phase 1, open-label, sequential ascending dose-escalation study. Designed to evaluate the safety and efficacy of a single IV infusion of investigational gene therapy HMI-203. Males, ages 18 to 45 years inclusive, with MPS II (Hunter syndrome) currently receiving idursulfase ERT (or the equivalent) are eligible to participate. Participants will be followed for safety and efficacy for 5 years.
The 3 groups in the trial
- HMI-203 Low Dose Level Cohort 1Treatment being tested
Treatment: Genetic HMI-203
- HMI-203 Intermediate Dose Level Cohort 2Treatment being tested
Treatment: Genetic HMI-203
- HMI-203 High Dose Level Cohort 3Treatment being tested
Treatment: Genetic HMI-203
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-203 in ERT-Treated Adults With Mucopolysaccharidosis Type II (MPS II) (juMPStart Trial)
- Record updated
- 28 August 2023